Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H19N3S.2ClH |
Molecular Weight | 358.329 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN(C)CCCN1C2=C(SC3=C1N=CC=C3)C=CC=C2
InChI
InChIKey=NESOWNBCLCBENO-UHFFFAOYSA-N
InChI=1S/C16H19N3S.2ClH/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19;;/h3-5,7-10H,6,11-12H2,1-2H3;2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H19N3S |
Molecular Weight | 285.407 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL265 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7894260 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTHIPENDYL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.6 ng/mL |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTHIPENDYL serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.5 h |
unknown, oral |
PROTHIPENDYL unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1280 mg 1 times / day multiple, oral Studied dose Dose: 1280 mg, 1 times / day Route: oral Route: multiple Dose: 1280 mg, 1 times / day Sources: |
unhealthy, 20 years (range: 16-31 years) n = 10 Health Status: unhealthy Condition: long-standing behaviour disorders Age Group: 20 years (range: 16-31 years) Sex: M Population Size: 10 Sources: |
|
960 mg 1 times / day multiple, oral Studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: |
unhealthy, 26 years (range: 14-42 years) n = 10 Health Status: unhealthy Condition: long-standing behaviour disorders Age Group: 26 years (range: 14-42 years) Sex: F Population Size: 10 Sources: |
|
4 g single, oral Overdose |
unknown |
Other AEs: Adverse event... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Adverse event | grade 5 | 4 g single, oral Overdose |
unknown |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. | 2007 Jun |
|
Increased D-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. | 2009 Dec |
|
Psychotropic medication use among nursing home residents in Austria: a cross-sectional study. | 2009 May 21 |
|
A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification. | 2009 Sep |
|
Research on antipsychotics in India. | 2010 Jan |
|
The impact of perfectionism and anxiety traits on action monitoring in major depressive disorder. | 2010 Jul |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:45:30 GMT 2023
by
admin
on
Sat Dec 16 05:45:30 GMT 2023
|
Record UNII |
6Y73598336
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m9268
Created by
admin on Sat Dec 16 05:45:30 GMT 2023 , Edited by admin on Sat Dec 16 05:45:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID00148471
Created by
admin on Sat Dec 16 05:45:30 GMT 2023 , Edited by admin on Sat Dec 16 05:45:30 GMT 2023
|
PRIMARY | |||
|
1082713-52-7
Created by
admin on Sat Dec 16 05:45:30 GMT 2023 , Edited by admin on Sat Dec 16 05:45:30 GMT 2023
|
PRIMARY | |||
|
6Y73598336
Created by
admin on Sat Dec 16 05:45:30 GMT 2023 , Edited by admin on Sat Dec 16 05:45:30 GMT 2023
|
PRIMARY | |||
|
71587927
Created by
admin on Sat Dec 16 05:45:30 GMT 2023 , Edited by admin on Sat Dec 16 05:45:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |